We are live on ! Find out more
DCM

DAFNA Capital Management Portfolio holdings

AUM $524M
1-Year Est. Return 164.42%
This Fund
S&P 500
This Quarter Est. Return
-8.66%
1 Year Est. Return
+164.42%
3 Year Est. Return
+313.04%
5 Year Est. Return
+302.83%
10 Year Est. Return
+4,361.99%
AUM
$419M
AUM Growth
-$20.7M
Cap. Flow
+$25.1M
Cap. Flow %
5.99%
Top 10 Hldgs %
47.79%
Holding
85
New
13
Increased
17
Reduced
18
Closed
2
Avg Time Held
10.1 quarters
Top 10 Avg Time Held
6.2 quarters
Top 20 Avg Time Held
10.5 quarters

Top Buys

Rank Stock Value
1
ATRC icon
AtriCure
ATRC
+$8.5M
2
URGN icon
UroGen Pharma
URGN
+$6.67M
3
BHVN icon
Biohaven
BHVN
+$3.95M
4
ALKS icon
Alkermes
ALKS
+$2.96M
5
SLRN icon
ACELYRIN
SLRN
+$2.3M

Top Sells

Rank Stock Value
1
PRCT icon
Procept Biorobotics
PRCT
+$2.44M
2
TNDM icon
Tandem Diabetes Care
TNDM
+$2.25M
3
BNTX icon
BioNTech
BNTX
+$1.57M
4
ASND icon
Ascendis Pharma A/S
ASND
+$1.56M
5
CATX icon
Perspective Therapeutics
CATX
+$1.14M

Sector Composition

Rank Sector Weight
1 Healthcare 85.73%
2 Miscellaneous 14.27%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow Held Since
XBI icon
1
State Street SPDR S&P Biotech ETF
XBI
$9.73B
$41.3M 9.86%
445,005
+13,790
+3% +$1.24M
2022 Q1
9 quarters
STXS icon
2
Stereotaxis
STXS
$104M
$24.9M 5.95%
13,680,554
– –
2013 Q2
44 quarters
MRUS icon
3
DELISTED
Merus
MRUS
$24.2M 5.79%
409,445
+30,450
+8% +$1.47M
2021 Q1
13 quarters
CYTK icon
4
Cytokinetics
CYTK
$8.78B
$21.6M 5.15%
398,100
– –
2021 Q3
11 quarters
RVMD icon
5
Revolution Medicines
RVMD
$41.8B
$19.9M 4.75%
511,894
– –
2020 Q4
14 quarters
IDYA icon
6
IDEAYA Biosciences
IDYA
$3.28B
$14.8M 3.54%
422,213
-24,128
-5% -$956K
2020 Q3
15 quarters
ATRC icon
7
AtriCure
ATRC
$2.93B
$14.6M 3.48%
639,173
+368,144
+136% +$8.5M
2013 Q2
44 quarters
IBB icon
8
iShares Biotechnology ETF
IBB
$10.4B
$14.1M 3.36%
102,500
– –
2016 Q4
30 quarters
SNDX icon
9
Syndax Pharmaceuticals
SNDX
$1.24B
$13.5M 3.22%
657,074
-2,500
-0.4% -$52.3K
2020 Q2
16 quarters
BPMC icon
10
DELISTED
Blueprint Medicines
BPMC
$11.3M 2.7%
104,763
-2,000
-2% -$200K
2016 Q4
30 quarters
ASND icon
11
Ascendis Pharma A/S
ASND
$14.9B
$11M 2.64%
80,972
-11,500
-12% -$1.56M
2021 Q4
10 quarters
XENE icon
12
Xenon Pharmaceuticals
XENE
$3.28B
$10.7M 2.55%
273,739
– –
2015 Q3
35 quarters
VKTX icon
13
Viking Therapeutics
VKTX
$3.31B
$10M 2.4%
189,117
-5,000
-3% -$328K
2018 Q4
22 quarters
NBIX icon
14
Neurocrine Biosciences
NBIX
$13.7B
$9.86M 2.36%
71,615
– –
2016 Q1
33 quarters
KALV icon
15
DELISTED
KalVista Pharmaceuticals
KALV
$9.51M 2.27%
806,973
– –
2021 Q1
13 quarters
DAWN icon
16
DELISTED
Day One Biopharmaceuticals
DAWN
$9.18M 2.19%
666,463
– –
2023 Q2
4 quarters
KURA icon
17
Kura Oncology
KURA
$861M
$8.72M 2.08%
423,500
+10,837
+3% +$223K
2017 Q3
27 quarters
TNDM icon
18
Tandem Diabetes Care
TNDM
$1.13B
$8.23M 1.97%
204,208
-54,000
-21% -$2.25M
2023 Q2
4 quarters
MORF icon
19
DELISTED
Morphic Holding, Inc. Common Stock
MORF
$7.9M 1.89%
231,748
– –
2020 Q4
14 quarters
URGN icon
20
UroGen Pharma
URGN
$1.86B
$7.87M 1.88%
+469,000
New +$6.67M
2024 Q2
0 quarters
BHVN icon
21
Biohaven
BHVN
$1.68B
$7.59M 1.81%
218,730
+100,000
+84% +$3.95M
2022 Q3
7 quarters
DXCM icon
22
DexCom
DXCM
$31.8B
$7.43M 1.78%
65,552
– –
2017 Q3
27 quarters
AXGN icon
23
Axogen
AXGN
$2.13B
$6.78M 1.62%
935,894
– –
2021 Q4
10 quarters
EWTX icon
24
Edgewise Therapeutics
EWTX
$4.04B
$5.23M 1.25%
290,197
-16,000
-5% -$279K
2022 Q1
9 quarters
LRMR icon
25
Larimar Therapeutics
LRMR
$221M
$4.64M 1.11%
639,974
-16,399
-2% -$126K
2018 Q2
24 quarters
1
2 3 4

Similar funds

4WM
49 Wealth Management Austin, Texas $524M AUM 16.59% 1-Year Est. Return
BB
Berkshire Bank Pittsfield, Massachusetts $524M AUM 21.97% 1-Year Est. Return
A
Alongside Austin, Texas $525M AUM
HW
Hedeker Wealth Lincolnshire, Illinois $524M AUM 36.83% 1-Year Est. Return
DAM
Decagon Asset Management London, United Kingdom $525M AUM 50.51% 1-Year Est. Return
SDWIA
Schwarz Dygos Wheeler Investment Advisors Minneapolis, Minnesota $524M AUM 25.1% 1-Year Est. Return
SCA
Stieven Capital Advisors St. Louis, Missouri $524M AUM 29.72% 1-Year Est. Return
BHPW
Beverly Hills Private Wealth Beverly Hills, California $525M AUM 24.1% 1-Year Est. Return

DAFNA Capital Management's Q2 2024 Portfolio in Review

As of Q2 2024, DAFNA Capital Management held 85 positions worth $419M, down 4.7% from $439M the previous quarter. Its ten largest holdings account for 48% of the portfolio.

DAFNA Capital Management deployed $25.1M of net new capital in Q2 2024, opening 13 new positions and adding to 17 existing holdings. Its largest new stake was UroGen Pharma: 469,000 shares worth $7.87M.

By sector, the portfolio is most concentrated in Healthcare at 86% of assets, down from 86% a quarter earlier, followed by Miscellaneous.

On the sell side, the largest reduction was Procept Biorobotics, an estimated $2.44M trimmed.

  • DAFNA Capital Management's largest Q2 2024 buy was UroGen Pharma: 469,000 shares worth $7.87M.
  • DAFNA Capital Management added most to AtriCure in Q2 2024, an estimated $8.5M increase.
  • DAFNA Capital Management's biggest Q2 2024 reduction was Procept Biorobotics, cutting an estimated $2.44M.
  • DAFNA Capital Management fully exited BioNTech in Q2 2024, selling an estimated $1.57M.
  • DAFNA Capital Management's ten largest holdings make up 48% of its $419M portfolio in Q2 2024.
  • DAFNA Capital Management opened 13 new positions and closed 2 in Q2 2024.
  • DAFNA Capital Management's portfolio value fell 4.7% quarter-over-quarter to $419M.

Based on DAFNA Capital Management's 13F filing for Q2 2024, filed 14 Aug 2024.